Titre : Benzofuranes

Benzofuranes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Intellectual Disability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzofuranes : Questions médicales les plus fréquentes", "headline": "Benzofuranes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzofuranes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-05", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzofuranes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Amiodarone", "alternateName": "Amiodarone", "url": "https://questionsmedicales.fr/mesh/D000638", "about": { "@type": "MedicalCondition", "name": "Amiodarone", "code": { "@type": "MedicalCode", "code": "D000638", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.075" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dronédarone", "alternateName": "Dronedarone", "url": "https://questionsmedicales.fr/mesh/D000077764", "about": { "@type": "MedicalCondition", "name": "Dronédarone", "code": { "@type": "MedicalCode", "code": "D000077764", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.075.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Benzbromarone", "alternateName": "Benzbromarone", "url": "https://questionsmedicales.fr/mesh/D001553", "about": { "@type": "MedicalCondition", "name": "Benzbromarone", "code": { "@type": "MedicalCode", "code": "D001553", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.110" } } }, { "@type": "MedicalWebPage", "name": "Cantharidine", "alternateName": "Cantharidin", "url": "https://questionsmedicales.fr/mesh/D002193", "about": { "@type": "MedicalCondition", "name": "Cantharidine", "code": { "@type": "MedicalCode", "code": "D002193", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.125" } } }, { "@type": "MedicalWebPage", "name": "Citalopram", "alternateName": "Citalopram", "url": "https://questionsmedicales.fr/mesh/D015283", "about": { "@type": "MedicalCondition", "name": "Citalopram", "code": { "@type": "MedicalCode", "code": "D015283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.187" } } }, { "@type": "MedicalWebPage", "name": "Escitalopram", "alternateName": "Escitalopram", "url": "https://questionsmedicales.fr/mesh/D000089983", "about": { "@type": "MedicalCondition", "name": "Escitalopram", "code": { "@type": "MedicalCode", "code": "D000089983", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.203" } } }, { "@type": "MedicalWebPage", "name": "Fura-2", "alternateName": "Fura-2", "url": "https://questionsmedicales.fr/mesh/D016257", "about": { "@type": "MedicalCondition", "name": "Fura-2", "code": { "@type": "MedicalCode", "code": "D016257", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.250" } } }, { "@type": "MedicalWebPage", "name": "Griséofulvine", "alternateName": "Griseofulvin", "url": "https://questionsmedicales.fr/mesh/D006118", "about": { "@type": "MedicalCondition", "name": "Griséofulvine", "code": { "@type": "MedicalCode", "code": "D006118", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.275" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzofuranes", "alternateName": "Benzofurans", "code": { "@type": "MedicalCode", "code": "D001572", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Zhi Xu", "url": "https://questionsmedicales.fr/author/Zhi%20Xu", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, Guizhou, P.R. China." } }, { "@type": "Person", "name": "Wei Zhou", "url": "https://questionsmedicales.fr/author/Wei%20Zhou", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Guizhou Medical University, Guiyang 550025, Guizhou, P.R. China." } }, { "@type": "Person", "name": "Ashraf A Abbas", "url": "https://questionsmedicales.fr/author/Ashraf%20A%20Abbas", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Faculty of Science, Cairo University Giza 12613 Egypt kmdawood@sci.cu.edu.eg +20-2-35727556 +20-2-35676602." } }, { "@type": "Person", "name": "Kamal M Dawood", "url": "https://questionsmedicales.fr/author/Kamal%20M%20Dawood", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Faculty of Science, Cairo University Giza 12613 Egypt kmdawood@sci.cu.edu.eg +20-2-35727556 +20-2-35676602." } }, { "@type": "Person", "name": "Giovanni Luca Beretta", "url": "https://questionsmedicales.fr/author/Giovanni%20Luca%20Beretta", "affiliation": { "@type": "Organization", "name": "Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133 Milan, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Proxy-report in individuals with intellectual disability: A scoping review.", "datePublished": "2022-06-08", "url": "https://questionsmedicales.fr/article/35676858", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jar.13013" } }, { "@type": "ScholarlyArticle", "name": "Perspectives of practitioners on support for caregivers of children with intellectual disability.", "datePublished": "2024-08-30", "url": "https://questionsmedicales.fr/article/39221716", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4102/curationis.v47i1.2559" } }, { "@type": "ScholarlyArticle", "name": "Intellectual disabilities teaching for medical students: a scoping review.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/37915002", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12909-023-04766-4" } }, { "@type": "ScholarlyArticle", "name": "Novel SETBP1 mutation in a chinese family with intellectual disability.", "datePublished": "2023-10-05", "url": "https://questionsmedicales.fr/article/37798664", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12920-023-01649-x" } }, { "@type": "ScholarlyArticle", "name": "Trends in the prevalence of intellectual disability among children in Taiwan.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36478619", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jir.12998" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzofuranes", "item": "https://questionsmedicales.fr/mesh/D001572" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzofuranes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzofuranes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzofuranes", "description": "Comment diagnostiquer une intoxication aux benzofuranes ?\nQuels tests sont utilisés pour détecter les benzofuranes ?\nQuels symptômes indiquent une exposition aux benzofuranes ?\nLes benzofuranes sont-ils visibles sur des tests standards ?\nQuel rôle joue l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Intellectual+Disability&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzofuranes", "description": "Quels sont les symptômes courants des benzofuranes ?\nLes benzofuranes provoquent-ils des effets psychologiques ?\nY a-t-il des symptômes cutanés associés aux benzofuranes ?\nLes benzofuranes affectent-ils le système respiratoire ?\nLes symptômes varient-ils selon la dose de benzofuranes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Intellectual+Disability&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzofuranes", "description": "Comment prévenir l'exposition aux benzofuranes ?\nLes travailleurs doivent-ils être formés sur les benzofuranes ?\nQuelles mesures de sécurité sont recommandées en laboratoire ?\nLes benzofuranes sont-ils réglementés ?\nComment gérer les déchets contenant des benzofuranes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Intellectual+Disability&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzofuranes", "description": "Quel traitement est recommandé pour l'intoxication aux benzofuranes ?\nDes antidotes existent-ils pour les benzofuranes ?\nComment traiter les symptômes neurologiques causés par les benzofuranes ?\nLes soins d'urgence sont-ils nécessaires pour l'exposition aux benzofuranes ?\nLa décontamination est-elle nécessaire après exposition ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Intellectual+Disability&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzofuranes", "description": "Quelles complications peuvent survenir après exposition aux benzofuranes ?\nLes benzofuranes peuvent-ils causer des maladies chroniques ?\nY a-t-il des effets à long terme des benzofuranes ?\nLes benzofuranes peuvent-ils affecter la reproduction ?\nComment surveiller les complications liées aux benzofuranes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Intellectual+Disability&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzofuranes", "description": "Qui est à risque d'exposition aux benzofuranes ?\nLes benzofuranes sont-ils présents dans des produits courants ?\nL'âge influence-t-il la sensibilité aux benzofuranes ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes benzofuranes affectent-ils différemment les sexes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Intellectual+Disability&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication aux benzofuranes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'exposition et les tests toxicologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les benzofuranes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses de sang et d'urine peuvent être effectuées pour détecter ces composés." } }, { "@type": "Question", "name": "Quels symptômes indiquent une exposition aux benzofuranes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des nausées et des palpitations." } }, { "@type": "Question", "name": "Les benzofuranes sont-ils visibles sur des tests standards ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, des tests spécifiques sont nécessaires pour détecter les benzofuranes." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à établir un lien entre les symptômes et l'exposition aux benzofuranes." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des benzofuranes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des vertiges, des maux de tête et des troubles de la vision." } }, { "@type": "Question", "name": "Les benzofuranes provoquent-ils des effets psychologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent causer de l'anxiété, des hallucinations et des troubles de l'humeur." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés aux benzofuranes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées et des démangeaisons peuvent survenir après exposition." } }, { "@type": "Question", "name": "Les benzofuranes affectent-ils le système respiratoire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent provoquer des difficultés respiratoires et une irritation des voies respiratoires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon la dose de benzofuranes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gravité des symptômes dépend de la dose et de la durée d'exposition." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux benzofuranes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire." } }, { "@type": "Question", "name": "Les travailleurs doivent-ils être formés sur les benzofuranes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une formation sur les risques et les mesures de sécurité est essentielle." } }, { "@type": "Question", "name": "Quelles mesures de sécurité sont recommandées en laboratoire ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des hottes, des gants et des lunettes de protection lors de la manipulation." } }, { "@type": "Question", "name": "Les benzofuranes sont-ils réglementés ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, leur utilisation est souvent réglementée en raison de leur toxicité potentielle." } }, { "@type": "Question", "name": "Comment gérer les déchets contenant des benzofuranes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les déchets doivent être éliminés selon les protocoles de gestion des déchets dangereux." } }, { "@type": "Question", "name": "Quel traitement est recommandé pour l'intoxication aux benzofuranes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement comprend l'élimination de l'exposition et des soins symptomatiques." } }, { "@type": "Question", "name": "Des antidotes existent-ils pour les benzofuranes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzofuranes." } }, { "@type": "Question", "name": "Comment traiter les symptômes neurologiques causés par les benzofuranes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour gérer les symptômes neurologiques." } }, { "@type": "Question", "name": "Les soins d'urgence sont-ils nécessaires pour l'exposition aux benzofuranes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins d'urgence peuvent être nécessaires en cas d'exposition sévère." } }, { "@type": "Question", "name": "La décontamination est-elle nécessaire après exposition ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la décontamination est essentielle pour réduire l'absorption des benzofuranes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après exposition aux benzofuranes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques, respiratoires et dermatologiques peuvent survenir." } }, { "@type": "Question", "name": "Les benzofuranes peuvent-ils causer des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut augmenter le risque de maladies chroniques." } }, { "@type": "Question", "name": "Y a-t-il des effets à long terme des benzofuranes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets à long terme incluent des troubles cognitifs et des problèmes respiratoires." } }, { "@type": "Question", "name": "Les benzofuranes peuvent-ils affecter la reproduction ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent qu'ils peuvent avoir des effets néfastes sur la reproduction." } }, { "@type": "Question", "name": "Comment surveiller les complications liées aux benzofuranes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier est recommandé pour détecter les complications précoces." } }, { "@type": "Question", "name": "Qui est à risque d'exposition aux benzofuranes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en laboratoire et ceux manipulant des produits chimiques sont à risque." } }, { "@type": "Question", "name": "Les benzofuranes sont-ils présents dans des produits courants ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être présents dans certains produits chimiques et médicaments." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité aux benzofuranes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus sensibles." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies respiratoires ou neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les benzofuranes affectent-ils différemment les sexes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que les effets peuvent varier entre les sexes, mais les données sont limitées." } } ] } ] }

Sources (7552 au total)

Proxy-report in individuals with intellectual disability: A scoping review.

Views can be collected from individuals (self-report) or others on their behalf (proxy-report).... We aimed to review the literature on methods and statistical approaches used to evaluate observer versus self-report responses from individuals with intellectual disability or Down syndrome.... A series of key questions related to statistical approaches and data collection methods were formulated a priori to inform the search strategy and review process. These addressed the topics of self-re... Fifty relevant original articles were identified which addressed at least one key question. Study details, including: research design, internal validity, external validity, and relevant results are pr... Few studies identified to-date have used self-report from individuals with Down syndrome, but lessons from the existing intellectual disability literature can guide researchers to incorporate self-rep...

Perspectives of practitioners on support for caregivers of children with intellectual disability.

Children with profound intellectual disabilities are unable to do anything for themselves and require full-time care in healthcare facilities. While caring for children, secondary caregivers become ov... This study aims to explore and describe the perspectives of mental healthcare practitioners regarding the conditions under which secondary caregivers of children with profound intellectual disabilitie... A qualitative-exploratory-descriptive and contextual research design was adopted using a non-probability purposive sampling technique. This study was conducted in Gauteng province. Semi-structured ind... Knowledge and skills development, stress reduction, resources and motivation were themes that emerged.... This study explored and described the perspectives of mental healthcare practitioners regarding the conditions under which secondary caregivers of children with profound intellectual disabilities work...

Intellectual disabilities teaching for medical students: a scoping review.

People with intellectual disabilities are a marginalized group whose health experiences and outcomes are poor. Lack of skill and knowledge in the healthcare workforce is a contributing factor. In Engl... We included any study from 1980 onwards which reported an educational intervention on intellectual disability, or intellectual disability and autism, for medical students from any year group. Database... We found a variety of intervention types: classroom-based teaching, simulation, placement, home visits, and panel discussions. There was substantial variation in content. Most studies involved lived e... There is a need for more consistency in intervention design, and higher quality evaluation of teaching in this area. Our review has drawn attention to the variety in teaching on this topic area and fu...

Novel SETBP1 mutation in a chinese family with intellectual disability.

Intellectual disability (ID) is characterized by an IQ < 70, which implies below-average intellectual function and a lack of skills necessary for daily living. ID may occur due to multiple causes, suc... To find the cause of genetic ID in a family, we performed whole-exome sequencing and Sanger sequencing to confirm the presence of a SETBP1 variant and real-time quantitative polymerase chain reaction ... A novel variant, c.942_943insGT (p. Asp316TrpfsTer28), was found in SETBP1. Furthermore, we observed that SETBP1 expression in patients was only 20% that of normal controls (P < 0.05).... A heterozygous variant in SETBP1 associated with ID was found. This report provides further evidence for its genetic basis and support for clinical genetic diagnosis....

Trends in the prevalence of intellectual disability among children in Taiwan.

Intellectual disability (ID) is a major developmental disability. However, data on changes in the prevalence over time at the national level are limited.... Using data from the national disability registry, we conducted an ecological study to evaluate the time trends of ID among children in Taiwan. We calculated the prevalence of ID by age, sex and severi... During the study period, the overall prevalence of ID in children aged 3-17 years increased from 3.60 to 5.91 per 1000 (β = 0.22, P < 0.001, r... The prevalence of ID in Taiwanese children increased from 2000 to 2011 and was largely attributable to increases in MID. Boys had a higher prevalence of ID and were more likely to have MID....

Personal and sexual boundaries: the experiences of people with intellectual disabilities.

Previous research shows that people with intellectual disabilities have less knowledge about sexual health and are more vulnerable to victimisation. In cases of sexual abuse, they are likely to encoun... The study had a qualitative design. Data were collected from seven people with mild intellectual disabilities (25-40 years; 2 men, five women) through one-to-one interviews in specialised health care ... The interviews identified that the participants want to be in romantic relationships and that some, consider sex to be unimportant. Many of them have had trouble finding someone to have a romantic rel... This study highlights the need for information about sexually abusive relationships, risks online and ways to get help. More attention should be given to the impact of trauma, police and mental health...

The feasibility of daily monitoring in adolescents and young adults with mild intellectual disability or borderline intellectual functioning.

It is unclear whether the limitations of young persons with a mild intellectual disability or borderline intellectual functioning preclude feasibility of the daily diary method.... For 60 consecutive days, 50 participants (M... Average compliance was 70.4%, while 26% of participants dropped out. Compliance was good in ambulatory (88.9%) and residential care (75.6%), but not in the juvenile detention setting (19.4%). The cont... Daily monitoring is feasible for individuals with a mild intellectual disability or borderline intellectual functioning receiving ambulatory or residential care, and can provide scientists and practit...

Exploring the psychometric properties of the Intellectual Disability versions of the Short Warwick-Edinburgh Mental Wellbeing Scale and Kidscreen10, self-reported by adolescents with intellectual disability.

There are no validated self-report measures that can be used to assess health and wellbeing in adolescents with intellectual disability (ID).... The aim of this study was to explore the psychometric properties of two newly adapted self-report health-related quality of life (HRQoL) and mental wellbeing measures: the Intellectual Disability vers... Confirmatory factor analysis (CFA) was conducted to validate the factor structure of both measures. Internal consistency was assessed using Cronbach's alpha and test-retest reliability was analysed us... The results of this study indicate that the ID-SWEMWBS and ID-Kidscreen10 have very good psychometric properties and can be used as self-report measures to assess HRQoL and mental wellbeing in adolesc...

Critiquing representations of intellectual disability in occupation-based literature.

Within and beyond occupation-based scholarship, concerns abound regarding the pervasiveness of discourses that promote a negative, deficit-based view of intellectual disability and associated conseque... This paper critically analyses representations of intellectual disability within occupation-based literature. It considers the influence of such representations on the occupational possibilities of pe... This review employed a critical interpretive synthesis of 21 peer-reviewed articles from occupational therapy and occupational science that focused on intellectual disability.... Three analytic threads were identified as contributing to how intellectual disability was represented across the reviewed literature:... Occupation-based discourses have powerful influence within society, particularly within occupational therapy, regarding understandings of intellectual disability and how these shape occupational possi...